These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 20530444)
1. Erlotinib in the treatment of non-small cell lung cancer: current status and future developments. Gridelli C; Maione P; Bareschino MA; Schettino C; Sacco PC; Ambrosio R; Barbato V; Falanga M; Rossi A Anticancer Res; 2010 Apr; 30(4):1301-10. PubMed ID: 20530444 [TBL] [Abstract][Full Text] [Related]
2. Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Di Maio M; Gridelli C; Normanno N; Perrone F; Ciardiello F J Cell Physiol; 2005 Dec; 205(3):355-63. PubMed ID: 15895392 [TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836 [TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. Yi HG; Kim HJ; Kim YJ; Han SW; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Kim CS; Heo DS; Bang YJ Lung Cancer; 2009 Jul; 65(1):80-4. PubMed ID: 19059670 [TBL] [Abstract][Full Text] [Related]
5. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626 [TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. Pao W; Miller VA J Clin Oncol; 2005 Apr; 23(11):2556-68. PubMed ID: 15767641 [TBL] [Abstract][Full Text] [Related]
7. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer. Smith J Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness and response predictive factors of erlotinib in a non-small cell lung cancer unselected European population previously treated: a retrospective, observational, multicentric study. Cioffi P; Marotta V; Fanizza C; Giglioni A; Natoli C; Petrelli F; Grappasonni I J Oncol Pharm Pract; 2013 Sep; 19(3):246-53. PubMed ID: 23223401 [TBL] [Abstract][Full Text] [Related]
9. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Yauch RL; Januario T; Eberhard DA; Cavet G; Zhu W; Fu L; Pham TQ; Soriano R; Stinson J; Seshagiri S; Modrusan Z; Lin CY; O'Neill V; Amler LC Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8686-98. PubMed ID: 16361555 [TBL] [Abstract][Full Text] [Related]
10. Predicting clinical benefit in non-small-cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors. Amler LC; Goddard AD; Hillan KJ Cold Spring Harb Symp Quant Biol; 2005; 70():483-8. PubMed ID: 16869787 [TBL] [Abstract][Full Text] [Related]
11. Erlotinib antitumor activity in non-small cell lung cancer models is independent of HER1 and HER2 overexpression. Friess T; Scheuer W; Hasmann M Anticancer Res; 2006; 26(5A):3505-12. PubMed ID: 17094474 [TBL] [Abstract][Full Text] [Related]
12. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Giaccone G; Gallegos Ruiz M; Le Chevalier T; Thatcher N; Smit E; Rodriguez JA; Janne P; Oulid-Aissa D; Soria JC Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6049-55. PubMed ID: 17062680 [TBL] [Abstract][Full Text] [Related]
13. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Hirsch FR; Varella-Garcia M; Cappuzzo F Oncogene; 2009 Aug; 28 Suppl 1():S32-7. PubMed ID: 19680294 [TBL] [Abstract][Full Text] [Related]
14. Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors. Chang MH; Ahn HK; Lee J; Jung CK; Choi YL; Park YH; Ahn JS; Park K; Ahn MJ Cancer; 2011 Jan; 117(1):143-51. PubMed ID: 20803614 [TBL] [Abstract][Full Text] [Related]
15. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer. Mu XL; Li LY; Zhang XT; Wang MZ; Feng RE; Cui QC; Zhou HS; Guo BQ Clin Cancer Res; 2005 Jun; 11(12):4289-94. PubMed ID: 15958609 [TBL] [Abstract][Full Text] [Related]
16. Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go. Patel JD; Pasche B; Argiris A Crit Rev Oncol Hematol; 2004 Jun; 50(3):175-86. PubMed ID: 15182824 [TBL] [Abstract][Full Text] [Related]
17. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. Herbst RS; Prager D; Hermann R; Fehrenbacher L; Johnson BE; Sandler A; Kris MG; Tran HT; Klein P; Li X; Ramies D; Johnson DH; Miller VA; J Clin Oncol; 2005 Sep; 23(25):5892-9. PubMed ID: 16043829 [TBL] [Abstract][Full Text] [Related]